Vaxcyte Inc. (PCVX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PCVX Stock Price Chart Interactive Chart >
PCVX Price/Volume Stats
| Current price | $38.70 | 52-week high | $49.31 |
| Prev. close | $37.59 | 52-week low | $17.44 |
| Day low | $37.17 | Volume | 749,000 |
| Day high | $39.00 | Avg. volume | 651,204 |
| 50-day MA | $43.08 | Dividend yield | N/A |
| 200-day MA | $33.95 | Market Cap | 3.10B |
Vaxcyte Inc. (PCVX) Company Bio
Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.
Latest PCVX News From Around the Web
Below are the latest news stories about VAXCYTE INC that investors may wish to consider to help them evaluate PCVX as an investment opportunity.
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call TranscriptVaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Good afternoon. My name is Lisa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full Year 2022 Financial Results Conference Call. All lines have been placed on mute […] |
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update-- Company Received U.S. Food and Drug Administration (FDA) Clearance of VAX-24 Infant Investigational New Drug (IND) Application and Expects to Initiate Phase 2 Study in Second Quarter 2023 -- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-24 Phase 2 Study in Adults 65 and Older on Track for Second Quarter 2023 -- -- Positive Topline Results from VAX-24 Phase 1/2 Proof-of-Concept Study in Adults Aged 18-64 Indicate Potential Best-in-Class Profile and Validate Company’s Carr |
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2 Proof-of-Concept Study Results in Adults, FDA Supported Initiation of Pediatric Program in Infants -- SAN CARLOS, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ |
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023SAN CARLOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on February 27, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial |
Vaxcyte to Present at the SVB Securities Global Biopharma ConferenceSAN CARLOS, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 3:00 p.m. ET / 12:00 p.m. PT. A live webcast of the presentation can be accessed through the Investors & Media |
PCVX Price Returns
| 1-mo | -12.48% |
| 3-mo | -16.74% |
| 6-mo | 55.05% |
| 1-year | 56.49% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -19.29% |
| 2022 | 101.56% |
| 2021 | -10.46% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...